ES2422299T3 - Indoles (4,5-dihidro) indoles tricíclicos - Google Patents

Indoles (4,5-dihidro) indoles tricíclicos

Info

Publication number
ES2422299T3
ES2422299T3 ES07847308T ES07847308T ES2422299T3 ES 2422299 T3 ES2422299 T3 ES 2422299T3 ES 07847308 T ES07847308 T ES 07847308T ES 07847308 T ES07847308 T ES 07847308T ES 2422299 T3 ES2422299 T3 ES 2422299T3
Authority
ES
Spain
Prior art keywords
formula
group
hydrogen atom
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07847308T
Other languages
English (en)
Inventor
Ermes Vanotti
Marina Caldarelli
Francesco Casuscelli
Barbara Forte
Maria Menichincheri
Alessandra Scolaro
Gabriella Traquandi
Paola Vianello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerviano Medical Sciences SRL
Original Assignee
Nerviano Medical Sciences SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences SRL filed Critical Nerviano Medical Sciences SRL
Application granted granted Critical
Publication of ES2422299T3 publication Critical patent/ES2422299T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula (I): **Fórmula** en la que el anillo A representa un heterociclo condensado de la fórmula IIa, IIb, III o IV: **Fórmula** R1 representa un átomo de hidrógeno o un grupo opcionalmente sustituido seleccionado de grupo alquilo,cicloalquilo, alquenilo, alquinilo, heterociclilo, arilo, heterocicliloxi-alquilo y alcoxicarbonilo; R2 es átomo de hidrógeno o de halógeno o un grupo de fórmula -COOR5 o -CONHR5, donde R5 representa uno delos significados definidos antes para R1, o un grupo arilo o heterociclilo opcionalmente sustituido; R3 es átomo de hidrógeno o un grupo de fórmula - CHO, -COOR5 o-CONHR5, donde R5 es como se ha definidoantes; R4 es átomo de hidrógeno o NHR6, donde R6 es átomo de hidrógeno o un grupo alquilo, arilo o heterocicliloopcionalmente sustituido.
ES07847308T 2006-11-28 2007-11-23 Indoles (4,5-dihidro) indoles tricíclicos Active ES2422299T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06124947 2006-11-28
PCT/EP2007/062762 WO2008065054A1 (en) 2006-11-28 2007-11-23 Tricyclic indoles and (4,5-dihydro) indoles

Publications (1)

Publication Number Publication Date
ES2422299T3 true ES2422299T3 (es) 2013-09-10

Family

ID=38921744

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07847308T Active ES2422299T3 (es) 2006-11-28 2007-11-23 Indoles (4,5-dihidro) indoles tricíclicos

Country Status (5)

Country Link
US (1) US8207180B2 (es)
EP (1) EP2118102B1 (es)
JP (1) JP5284973B2 (es)
ES (1) ES2422299T3 (es)
WO (1) WO2008065054A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7974235B2 (en) * 2006-11-13 2011-07-05 Telecommunication Systems, Inc. Secure location session manager
US8084621B2 (en) * 2006-12-04 2011-12-27 Jiangsu Simcere Pharmaceutical R&D Co. Ltd. 3-Pyrrolo[b]cyclohexylene-2-dihydroindolinone derivatives and uses thereof
WO2008104475A1 (en) * 2007-02-27 2008-09-04 Nerviano Medical Sciences S.R.L. Isoquinolinopyrrolopyridinones active as kinase inhibitors
DE102008027331A1 (de) * 2008-06-07 2009-12-10 Friedrich-Alexander-Universität Erlangen-Nürnberg Verwendung von Indol-3-carbonsäureestern zur Hemmung der mikrosomalen Prostaglandin E2 Synthase
EP2417125B1 (en) * 2009-03-27 2015-09-09 Nerviano Medical Sciences S.r.l. N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as mps1 kinase inhibitors
WO2011067145A1 (en) * 2009-12-04 2011-06-09 Nerviano Medical Sciences S.R.L. Tricyclopyrazole derivatives
CN103038643A (zh) * 2010-04-16 2013-04-10 基因泰克公司 作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
CN103339134B (zh) * 2011-01-26 2015-12-23 内尔维阿诺医学科学有限公司 三环吡咯并衍生物、它们的制备方法和它们作为激酶抑制剂的应用
EP2668188B1 (en) * 2011-01-26 2016-05-18 Nerviano Medical Sciences S.r.l. Tricyclic derivatives, process for their preparation and their use as kinase inhibitors
WO2013049559A1 (en) 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
IN2014DN06898A (es) 2012-03-14 2015-05-15 Salk Inst For Biological Studi
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
CN106132963B (zh) 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
WO2017033019A1 (en) 2015-08-26 2017-03-02 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) Condensed tricyclic compounds as protein kinase inhibitors
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
JP6900406B2 (ja) * 2016-06-16 2021-07-07 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
JP7794421B2 (ja) 2016-12-12 2026-01-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
EP3725791B1 (en) * 2017-12-13 2023-03-15 Harbin Zhenbao Pharmaceutical Co., Ltd. Salt serving as akt inhibitor and crystal thereof
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
US12533353B2 (en) 2018-09-24 2026-01-27 Carna Biosciences, Inc. Methods of treatment of cancer comprising CDC7 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
WO2008065054A1 (en) 2008-06-05
EP2118102A1 (en) 2009-11-18
US20100075998A1 (en) 2010-03-25
JP2010527324A (ja) 2010-08-12
EP2118102B1 (en) 2013-06-12
JP5284973B2 (ja) 2013-09-11
US8207180B2 (en) 2012-06-26

Similar Documents

Publication Publication Date Title
ES2422299T3 (es) Indoles (4,5-dihidro) indoles tricíclicos
PE20130155A1 (es) Derivados de ariletinilo
SV2010003459A (es) Derivados de pirimidina 934
NI200700242A (es) Derivados de cumarina sustituidos con tiadiazol y sus usos como inhibidores de la biosíntesis de leucotrienos.
CO6180506A2 (es) Inhibidores de la proteasa ns3 del hcv
CO6231035A2 (es) Novedoso compuesto heteromonociclico que tiene propiedades superiores como agente farmaceutico
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
CR20110049A (es) Derivados de benzazepina y su uso como antagonistas de histamina h3
PE20200388A1 (es) Amidas heterociclicas de 5 miembros y biciclicas como inhibidores de rock
MX2010005025A (es) Composicion fungicida y metodo para el control de hongos nocivos.
CO6321130A2 (es) Piridinas carboxamidas como inhibidores de la 11 beta-hsd1
GT200500286A (es) Analogos de anilino-pirimidina
PE20121506A1 (es) Compuestos triazolopiridinas como inhibidores de c-met
AR058562A1 (es) Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
PE20121312A1 (es) Metodo para preparar compuestos macrociclicos inhibidores de serina proteasas de hepatitis c
ECSP088559A (es) Derivados de pirimidina
BR112014006660A2 (pt) novos derivados de dihidroquinolina-2-ona bicíclicos
SV2009003373A (es) COMPUESTOS AMINO-5-[-4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5- FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA REF. AM102759
AR074435A1 (es) Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer.
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
EA200971101A1 (ru) Соединения на основе лантибиотиков, обладающие противомикробной активностью
CO6220949A2 (es) Derivados pirazolicos como inhibidores de la 11 beta -hsd1
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
CO6362009A2 (es) Derivados de morfolinopurina
ECSP11011318A (es) Derivados de benzofurano